Literature DB >> 280378

Immunotherapy of leukaemias: present status and future prospects.

H D Flad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 280378     DOI： 10.1007/bf01539658

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


× No keyword cloud information.
  11 in total

1.  Immunotherapy of chronic myelocytic leukemia: effects of different vaccination schedules.

Authors:  J E Sokal; C W Aungst; M Snyderman; G Gomez
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

2.  MER and other mycobacterial fractions in the immunotherapy of cancer.

Authors:  D W Weiss
Journal:  Med Clin North Am       Date:  1976-05       Impact factor: 5.456

3.  The immune response in acute myelocytic leukemia: effect of the methanol extraction residue fraction of tubercle bacilli (MER) on T and B cell functions and their relation to the course of the disease.

Authors:  G Izak; Y Stupp; N Manny; G Zajicek; D W Weiss
Journal:  Isr J Med Sci       Date:  1977-07

4.  Active immunotherapy for acute lymphoblastic leukaemia.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; A Cattan; J R Schlumberger; M Hayat; F De Vassal
Journal:  Lancet       Date:  1969-04-05       Impact factor: 79.321

5.  Management of adult acute myelogenous leukaemia.

Authors:  D Crowther; R L Powles; C J Bateman; M E Beard; C L Gauci; P F Wrigley; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1973-01-20

6.  Infection and second-remission rates in patients having immunotherapy for acute myeloid keukemia.

Authors:  D A Galton; H E Kay; P Reizenstein; M Penchansky; W R Vogler; J A Whittaker
Journal:  Lancet       Date:  1977-11-05       Impact factor: 79.321

7.  Letter: Bone-marrow culture in acute myeloid leukaemia.

Authors:  J M Goldman; N A Buskard; K H Th'ng
Journal:  Lancet       Date:  1976-07-31       Impact factor: 79.321

8.  The immunotherapy of acute myelogenous leukaemia using intravenous BCG.

Authors:  J A Whittaker; A J Slater
Journal:  Br J Haematol       Date:  1977-02       Impact factor: 6.998

9.  Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.

Authors:  R L Powles; J Russell; T A Lister; T Oliver; J M Whitehouse; J Malpas; B Chapuis; D Crowther; P Alexander
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

10.  Immunotherapy for acute myelogenous leukaemia.

Authors:  R L Powles; D Crowther; C J Bateman; M E Beard; T J McElwain; J Russell; T A Lister; J M Whitehouse; P F Wrigley; M Pike; P Alexander; G H Fairley
Journal:  Br J Cancer       Date:  1973-11       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.